VRE bacteremia
Vancomycin-resistant Enterococcus faecium (VRE) is a leading cause of hospital-acquired bloodstream infection in immunocompromised, neutropenic, and critically ill patients, and it carries high mortality because therapeutic options are narrow. Frontline agents such as daptomycin and linezolid are increasingly compromised by daptomycin-nonsusceptible and linezolid-resistant strains, and VRE readily forms biofilms on catheters, heart valves, and prosthetic material that shield it from antibiotics. Lytic bacteriophages are well suited to this niche because they kill antibiotic-resistant E. faecium independent of its resistance mechanisms, are self-amplifying at the infection site, penetrate biofilm, and can resensitize resistant isolates to daptomycin. Their exquisite strain specificity also spares the gut microbiome, an advantage in patients whose VRE arises from intestinal domination.
How phages act here
Mechanism
Enterococcal phages (predominantly siphoviruses and herpesvirus-like lytic phages such as ENB6, the NV-497/NV-503 series, and clinical isolates Φ9184 and ΦHi3) adsorb to E. faecium surface receptors, often the enterococcal polysaccharide antigen or wall teichoic acids, then lyse the cell — activity that is independent of vancomycin or daptomycin resistance. Because adsorption is strain-specific, phages are deployed as multi-phage cocktails to broaden coverage and suppress emergence of phage resistance. A central, well-documented mechanism for VRE is phage-antibiotic synergy: phage selection pressure that drives loss of surface receptors or capsule simultaneously restores daptomycin and ceftaroline susceptibility (collateral sensitivity / "resensitization"), so phage plus daptomycin-ceftaroline achieves bactericidal killing and prevents both phage and antibiotic resistance in high-inoculum, biofilm, and simulated endocardial-vegetation models. Phages also degrade biofilm matrix and reach embedded cells that antibiotics cannot. Engineered and CRISPR-Cas phage approaches are an emerging angle aimed at broadening host range and sequence-specific killing, though for Enterococcus these remain preclinical.
Where it stands
Current evidence
Evidence is preclinical-plus-compassionate-use, not yet randomized-trial level. The foundational proof of concept (Biswas et al., Infection and Immunity 2002) showed a single dose of phage ENB6 rescued 100% of mice from lethal VRE bacteremia. A robust body of in vitro and ex vivo PK/PD work from the Rybak group (2020-2024) established phage-antibiotic synergy and daptomycin resensitization against daptomycin-nonsusceptible E. faecium using defined cocktails (ATCC 113, NV-497, NV-503-01, NV-503-2) with daptomycin plus ceftaroline. The most important human data is a 2024 mBio case report (Stellfox, Van Tyne et al., University of Pittsburgh): a 57-year-old immunocompromised woman with 7 years of recurrent VRE bacteremia received IV/oral siphoviruses Φ9184 and ΦHi3 with daptomycin, achieving roughly four months of bacteremia-free improvement before neutralizing anti-phage IgG emerged and treatment was discontinued — demonstrating both feasibility and the anti-phage immunity limitation. As of 2026, enterococcal phage therapy in bacteremia remains personalized/compassionate-use under expanded access; the first registered enterococcal phage trial (NCT06942624) targets a chronic E. faecium periprosthetic joint infection, not bacteremia.
Evidence confidence: medium
The data
Key studies & trials
- Stellfox ME, Fernandes C, Shields RK, Haidar G, Hughes Kramer K, Dembinski E, Mangalea MR, Arya G, Canfield GS, Duerkop BA, Van Tyne D. Bacteriophage and antibiotic combination therapy for recurrent Enterococcus faecium bacteremia. mBio. 2024;15(3):e03396-23. PMID: 38353560. ↗
- Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infection and Immunity. 2002;70(1):204-210. PMID: 11748184. ↗
- Kunz Coyne AJ, Stamper K, El Ghali A, Kebriaei R, Biswas B, Wilson M, Deschenes MV, Tran TT, Arias CA, Rybak MJ. Phage-antibiotic cocktail rescues daptomycin and phage susceptibility against daptomycin-nonsusceptible Enterococcus faecium in a simulated endocardial vegetation ex vivo model. Microbiology Spectrum. 2023;11(4):e00340-23. PMID: 37338375. ↗
- Orthopaedic Innovation Centre. Phage Therapy for the Treatment of a Chronic Enterococcus faecium Periprosthetic Joint Infection. ClinicalTrials.gov identifier NCT06942624; registered 2025. ↗
Who is working on it
Programs & centers
The possibility
The most compelling near-term promise is using phages as a daptomycin 'resensitizer': pairing a tailored enterococcal phage cocktail with daptomycin plus ceftaroline could turn untreatable, daptomycin-resistant VRE endocarditis and line infections back into curable disease while blocking the evolution of further resistance. As rapid phage-susceptibility matching and clinical phage banks mature, personalized cocktails could be assembled within days of a positive blood culture, and decolonizing the gut reservoir that seeds VRE bloodstream infection becomes a realistic adjunct. The key obstacle — neutralizing anti-phage antibodies seen in the Pittsburgh case — is steering the field toward phage rotation, engineered or immune-evading phages, and earlier, time-limited courses to capture benefit before adaptive immunity blunts it.